Abstract: An imaging system, such as a surgical microscope, laparoscope, or endoscope or integrated with these devices, includes an illuminator providing patterned white light and/or fluorescent stimulus light. The system receives and images light hyperspectrally, in embodiments using a hyperspectral imaging array, and/or using narrowband tunable filters for passing filtered received light to an imager. Embodiments may construct a 3-D surface model from stereo images, and will estimate optical properties of the target using images taken in patterned light or using other approximations obtained from white light exposures. Hyperspectral images taken under stimulus light are displayed as fluorescent images, and corrected for optical properties of tissue to provide quantitative maps of fluorophore concentration. Spectral information from hyperspectral images is processed to provide depth of fluorophore below the tissue surface. Quantitative images of fluorescence at depth are also prepared.

Abstract: A method of generating corrected fluorescence data of concentrations of a targeted fluorophore in tissue of a subject includes administering first and second fluorescent contrast agents to the subject, the first contrast agent targeted to tissue of interest, the second agent untargeted. The tissue is illuminated with light of a first stimulus wavelength and first data is acquired at an appropriate emissions wavelength; the tissue is illuminated at a second stimulus wavelength and second data is acquired at a second emissions wavelength associated with the second agent, the first and second emissions wavelength differ. Difference data is generated by subtracting the second data from the first data. A system provides for stimulus and capture at multiple wavelengths, with image storage memory and subtraction code, to perform the method. Corrected data may form an fluorescence image, or is used to generate fluorescence tomographic images.

Abstract: An aircraft and an aircraft wing assembly for an aircraft. The wing assembly includes a wing body assembly including a wing body; and at least one protruding portion connected to the wing body. The protruding portion extends aftwardly from an aft side of the wing body assembly, a leading edge of the wing body assembly defining a leading edge line, a trailing edge of the wing body assembly defining a trailing edge line extending between the inboard end and the outboard end, the trailing edge including a trailing edge of the protruding portion, the trailing edge line being a smooth line, a chord distance being defined longitudinally from the leading edge line to the trailing edge line, the chord distance at a center of the protruding portion being greater than the chord distance inboard of protruding portion and outboard of the protruding portion.

Abstract: A winglet system for a wing of an aircraft is provided. The winglet system comprises an attachment end for attachment to a main wing of the aircraft, an upper winglet and a lower winglet. The upper and lower winglets are staggered and also overlap one another along the chord of the attachment end. A spanwise profile of the lower winglet has a midpoint where a slope of the spanwise profile at a point outboard of the midpoint is inclined more upwardly than a slope of the spanwise profile at the midpoint. The configuration of the winglet system may provide benefits such as a reduced bending moment and reduced negative interference between the winglets while also managing ground clearance.

Abstract: An aircraft and an aircraft wing assembly for an aircraft. The wing assembly includes a wing body assembly including a wing body; and at least one protruding portion connected to the wing body. The protruding portion extends aftwardly from an aft side of the wing body assembly, a leading edge of the wing body assembly defining a leading edge line, a trailing edge of the wing body assembly defining a trailing edge line extending between the inboard end and the outboard end, the trailing edge including a trailing edge of the protruding portion, the trailing edge line being a smooth line, a chord distance being defined longitudinally from the leading edge line to the trailing edge line, the chord distance at a center of the protruding portion being greater than the chord distance inboard of protruding portion and outboard of the protruding portion.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.